台灣臨床試驗主持人資料庫|TPIDB

2018-08-31 - 2025-11-11

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
4Sites

Terminated4Sites

黃毓惠

Linkou Chang Gung Medical Foundation

Division of Dermatology

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2017-06-01 - 2024-04-08

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
10Sites

Terminated9Sites

林振源

China Medical University Hospital-Taipei

未分科

2018-04-24 - 2020-01-16

Phase III

Completed

Condition/Disease
Test Drug

Participate Sites
7Sites

Terminated7Sites

黃毓惠

Linkou Chang Gung Medical Foundation

Division of Dermatology

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2016-08-01 - 2020-12-31

Phase II

Completed

Condition/Disease
Test Drug

Participate Sites
6Sites

Terminated5Sites

陳訓徹

Linkou Chang Gung Medical Foundation

Division of General Surgery

2017-07-01 - 2022-07-30

Phase III

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease

Condition/Disease

Mild Alzheimer's Disease
Test Drug

Crenezumab

Participate Sites
7Sites

Terminated6Sites

黃錦章

Linkou Chang Gung Medical Foundation

Division of Neurology

胡朝榮

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Neurology

2017-06-28 - 2020-12-31

Phase I

A Phase I safety and tolerability study of T-1101 (Tosylate) as a powder for constitution (OPC) in patients with advanced refractory solid tumors

Condition/Disease

Advanced Refractory Solid Tumors
Test Drug

T-1101 (Tosylate)

Participate Sites
5Sites

Suspended4Sites

白禮源

China Medical University Hospital-Taipei

未分科

趙祖怡

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2016-08-31 - 2018-12-31

Phase II

Multi-center, randomized, vehicle-controlled, investigator-blinded, parallel groups study to evaluate the efficacy and safety of NP000888 in subjects with plaque and nail psoriasis

Condition/Disease

Psoriasis or nail psoriasis
Test Drug

NP000888

Participate Sites
11Sites

Terminated11Sites

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2019-04-01 - 2022-05-31

Phase III

A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.

Condition/Disease

idiopathic pulmonary fibrosis
Test Drug

GLPG1690 (G451990)

Participate Sites
5Sites

Recruiting4Sites

許超群

Kaohsiung Municipal Gangshan Hospital

未分科

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2018-05-01 - 2023-09-30

Phase III

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)

Condition/Disease

TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer
Test Drug

Keytruda injection

Participate Sites
15Sites

Recruiting1Sites

Terminated13Sites

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2018-03-01 - 2021-06-30

Phase III

A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis

Condition/Disease

Atopic Dermatitis
Test Drug

Baricitinib (LY3009104)

Participate Sites
6Sites

Terminated6Sites

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

Search Result

List